Display options
Cite
Alzubi J, Dettmer-Monaco V, Kuehle J, et al. PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model. Mol Ther Oncolytics. 2020;18:226-235doi: 10.1016/j.omto.2020.06.014.
Alzubi, J., Dettmer-Monaco, V., Kuehle, J., Thorausch, N., Seidl, M., Taromi, S., Schamel, W., Zeiser, R., Abken, H., Cathomen, T., & Wolf, P. (2020). PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model. Molecular therapy oncolytics, 18226-235. https://doi.org/10.1016/j.omto.2020.06.014
Alzubi, Jamal, et al. "PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model." Molecular therapy oncolytics vol. 18 (2020): 226-235. doi: https://doi.org/10.1016/j.omto.2020.06.014
Alzubi J, Dettmer-Monaco V, Kuehle J, Thorausch N, Seidl M, Taromi S, Schamel W, Zeiser R, Abken H, Cathomen T, Wolf P. PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model. Mol Ther Oncolytics. 2020 Jun 24;18:226-235. doi: 10.1016/j.omto.2020.06.014. eCollection 2020 Sep 25. PMID: 32728611; PMCID: PMC7372156.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Oncolytics. 2020 Jun 24;18:226-235. doi: 10.1016/j.omto.2020.06.014. eCollection 2020 Sep 25.

PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model.

Molecular therapy oncolytics

Jamal Alzubi, Viviane Dettmer-Monaco, Johannes Kuehle, Niko Thorausch, Maximilian Seidl, Sanaz Taromi, Wolfgang Schamel, Robert Zeiser, Hinrich Abken, Toni Cathomen, Philipp Wolf

Affiliations

  1. Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, Freiburg, Germany.
  2. Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Freiburg, Germany.
  3. Center for Molecular Medicine, University of Cologne, Cologne, Germany.
  4. BIOSS Centre for Biological Signaling, University of Freiburg, Freiburg, Germany.
  5. Institute of Clinical Pathology, Medical Center-University of Freiburg, Freiburg, Germany.
  6. Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.
  7. Faculty of Medical and Life Sciences, University Furtwangen, Campus Schwenningen, Villingen-Schwenningen, Germany.
  8. Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  9. Department for Genetic Immunotherapy, Regensburg Center for Interventional Immunology, University of Regensburg, Regensburg, Germany.
  10. Department of Urology, Medical Center-University of Freiburg, Freiburg, Germany.

PMID: 32728611 PMCID: PMC7372156 DOI: 10.1016/j.omto.2020.06.014

Abstract

While chimeric antigen receptor (CAR) T cell immunotherapy targeting CD19 has shown remarkable success in patients with lymphoid malignancies, the potency of CAR T cells in solid tumors is low so far. To improve the efficacy of CAR T cells targeting prostate carcinoma, we designed a novel CAR that recognizes a new epitope in the prostate-specific membrane antigen (PSMA) and established novel paradigms to apply CAR T cells in a preclinical prostate cancer model.

© 2020 The Author(s).

Keywords: CAR T cells; chemotherapy; combination therapy; docetaxel; focal therapy; prostate cancer; prostate specific membrane antigen

References

  1. Immunol Lett. 2019 Aug;212:53-69 - PubMed
  2. Anticancer Res. 2018 Jan;38(1):61-69 - PubMed
  3. Prostate. 2010 Apr 1;70(5):562-9 - PubMed
  4. Clin Cancer Res. 2017 May 1;23(9):2255-2266 - PubMed
  5. Prostate. 2016 Oct;76(14):1257-70 - PubMed
  6. Hum Gene Ther. 2019 Aug;30(8):975-984 - PubMed
  7. Front Immunol. 2019 Feb 05;10:128 - PubMed
  8. Urology. 1996 Aug;48(2):326-34 - PubMed
  9. N Engl J Med. 2018 Feb 1;378(5):439-448 - PubMed
  10. Cancer Res. 2016 Apr 15;76(8):2087-93 - PubMed
  11. Nat Med. 2007 Dec;13(12):1440-9 - PubMed
  12. Prostate. 2004 Sep 15;61(1):12-25 - PubMed
  13. Prostate. 2014 Feb;74(3):286-96 - PubMed
  14. Mol Ther. 2010 Feb;18(2):413-20 - PubMed
  15. Cancer Res. 1997 Jun 15;57(12):2321-4 - PubMed
  16. Cancer Res. 2005 Oct 1;65(19):9080-8 - PubMed
  17. Cell Death Dis. 2019 Jun 17;10(7):476 - PubMed
  18. Front Med. 2017 Dec;11(4):554-562 - PubMed
  19. Cancer Res. 2015 Sep 15;75(18):3853-64 - PubMed
  20. Urol Oncol. 2014 Apr;32(3):272-9 - PubMed
  21. PLoS One. 2014 Oct 03;9(10):e109427 - PubMed
  22. Nat Med. 2019 Jun;25(6):947-953 - PubMed
  23. Semin Oncol. 2003 Oct;30(5):667-76 - PubMed
  24. Int J Cancer. 2016 Mar 15;138(6):1388-400 - PubMed
  25. Immunotherapy. 2013 Jan;5(1):27-38 - PubMed
  26. Cancer Res. 1999 Jul 1;59(13):3192-8 - PubMed
  27. EMBO J. 2006 Mar 22;25(6):1375-84 - PubMed
  28. Eur J Cancer. 2013 Jun;49(9):2223-32 - PubMed
  29. Front Immunol. 2018 Nov 08;9:2593 - PubMed
  30. J Immunother. 2010 Apr;33(3):262-71 - PubMed
  31. Cancer Res. 2007 Mar 1;67(5):2265-73 - PubMed
  32. Cancer Res. 2009 Dec 15;69(24):9385-94 - PubMed
  33. Nat Rev Drug Discov. 2015 Jul;14(7):499-509 - PubMed
  34. Prostate. 2011 May;71(6):588-96 - PubMed
  35. Cancer Immunol Res. 2015 Jan;3(1):68-84 - PubMed
  36. Oncotarget. 2016 Apr 19;7(16):22531-42 - PubMed
  37. Blood. 2013 Feb 14;121(7):1165-74 - PubMed
  38. JAMA. 2017 Jun 27;317(24):2532-2542 - PubMed
  39. Mol Ther. 2018 Jul 5;26(7):1855-1866 - PubMed
  40. Med Res Rev. 2019 Jan;39(1):40-69 - PubMed
  41. Nat Med. 2017 Apr 3;23(4):415-423 - PubMed
  42. Nat Med. 2019 Jan;25(1):82-88 - PubMed
  43. Hum Gene Ther. 2017 Nov;28(11):1105-1115 - PubMed
  44. Cancer Res. 2010 Dec 15;70(24):10170-81 - PubMed
  45. Sci Rep. 2014 Apr 11;4:4656 - PubMed
  46. Clin Cancer Res. 1997 Jan;3(1):81-5 - PubMed
  47. J Immunother. 2009 Jul-Aug;32(6):565-73 - PubMed
  48. N Engl J Med. 2018 Feb 1;378(5):449-459 - PubMed
  49. Gene Ther. 2010 Oct;17(10):1206-13 - PubMed
  50. Mol Ther. 2011 Apr;19(4):760-7 - PubMed
  51. Hum Gene Ther Methods. 2017 Dec;28(6):302-309 - PubMed
  52. J Immunother Cancer. 2019 Feb 11;7(1):42 - PubMed

Publication Types